can i take glp 1 if i'm not overweight ACP issues guidance on medications for obesity, GLP-1 drugs, even when they

Individual results vary based on metabolism, adherence, and genetic factors that influence GLP-1 receptor sensitivity

Can you use GLP-1 medications if you have Crohn's disease

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and